› $150,000,000 verdict in personal injury case
Depo-Provera (medroxyprogesterone acetate), the injectable contraceptive, has updated its safety label to include warnings of breast cancer risk and bone mineral density loss. The new label changes were approved by the Food and Drug Administration (FDA) and will go into effect immediately.
Hormone replacement therapy (HRT) is blamed for increasing a woman’s risk of breast and ovarian cancer, heart attacks and strokes. Now, a new research study shows the pills also increase women’s risk of developing painful kidney stones.
The reports of health problems associated with hormone replacement therapy (HRT) keep coming. First, the Women’s Health Initiative identified women who took the combined estrogen-plus-progestin therapy were at a much greater risk of developing breast cancer. It later showed these women were at an increased risk of heart disease and other serious health problems. Now, an article published online in the Journal of Clinical Oncology suggests that women who took combined HRT are at an increased risk of lung cancer by as much as 50 percent.
William T. Creasman was listed as the author of an article written by a freelance writer for the December 1998 Journal of Women’s Health. The title: “Is there an association between hormone replacement therapy and breast cancer?” The article points out that there is no “definitive evidence” that HRT is linked to breast cancer. But the dirty little secret behind that article in the medical journal is that Creasman didn’t actually write the article. It was authored by a writer for DesignWrite, a marketing firm that represented HRT-maker Wyeth, now owned by Pfizer. As the story was going to press, Wyeth was covering up evidence that proved otherwise. The drug company’s estrogen-plus-progestin HRT was, in fact, increasing a woman’s risk for breast cancer as well as heart disease and Alzheimer’s.
A study involving nearly 58,000 women in France over a 12-year period suggests that hormone replacement therapy (HRT) may increase a woman’s risk of developing asthma after menopause. Researchers from the Gustave Roussy Institute in France and the Instituto Nacional de Salud Publica in Mexico published the findings in the British medical journal, Thorax. The study suggested that women who took HRT were 21 percent more likely to develop asthma than women who did not take HRT. The risk was even greater for women who took estrogen-only HRT compared to the combined estrogen-plus-progestin therapy, with the estrogen-only group at 54 percent greater risk of developing asthma compared to women who did not take HRT. This is the first long-term, large-scale study to suggest that estrogen-only HRT puts women at much greater risk of asthma than the combined therapy.
There is plenty of bad press about hormone replacement therapy (HRT), a striking reversal of just a decade or two ago, when drug makers were touting the many benefits of HRT for menopausal women. Those drug makers spent millions of dollars developing advertising campaigns and paying doctors to write articles in medical journals claiming the pills that combined estrogen and progestin were the fountain of youth. They put an end to nasty menopause symptoms such as mood swings and hot flashes, and offered the added benefit of strengthening bones and protecting women against cancer and heart disease.
Drug companies’ advertisements touting the benefits of hormone replacement therapy (HRT) sold Delores Ann Spann Whatley of Tyler, Texas on the idea that her mood swings and hot flashes could be wiped away with just a daily pill. The estrogen-and-progestin cocktail was touted as a miracle drug, able to squash menopause symptoms while warding against osteoporosis, heart disease and cancer. But the pharmaceutical companies soon realized that the HRT that was making them rich was actually making consumers sick. But instead of notifying the public and pulling their product, the drug companies attempted to cover up the mounting statistics and continued to advertise to women about the benefits of HRT.
